• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Alpha Tau to Present at Jefferies Global Healthcare Conference

    5/28/25 8:30:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care
    Get the next $DRTS alert in real time by email

    JERUSALEM, May 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the Jefferies Global Healthcare Conference on June 5, 2025.

    Event:Jefferies Global Healthcare Conference
    Format:Presentation
    Date:June 5, 2025
    Time:1:25 – 1:55PM ET
    Location:New York, NY
      

    Mr. Levy will be available for 1x1 investor meetings. Please reach out to your Jefferies representative to schedule.

    About Alpha Tau Medical Ltd.

    Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

    About Alpha DaRT®

    Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

    Investor Relations Contact:

    [email protected]



    Primary Logo

    Get the next $DRTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRTS

    DatePrice TargetRatingAnalyst
    12/15/2023$8.00Buy
    Citigroup
    4/24/2023$9.00Buy
    H.C. Wainwright
    4/14/2022$20.00Overweight
    Cantor Fitzgerald
    4/8/2022$19.00Overweight
    Piper Sandler
    4/4/2022$21.00Buy
    Citigroup
    More analyst ratings